Opc-15161 is a novel superoxide generation inhibitor and major degradation product of OPC-15160.

OPC 8490 is a stimulant. OPC 8490 has a positive inotropic effect. OPC 8490 can be used for research on heart failure.

OP-1690 is a complete estrogen receptor (ERα) antagonist (CERAN), with pIC50 values of 7.5 and 7.9 in alkaline phosphatase (AP) activity assay and TR-FRET assay, respectively. OP-1690 modulates receptor function by inducing ERα tetramerization, effectively induces ERα degradation, inhibits target gene transcription, but exhibits low antiproliferative potency. OP-1690 can be used for breast cancer research.

ONO-2921 is an orally active and selective N-type calcium channel blocker. ONO-2921 functionally blocks N-type calcium channels. ONO-2921 reduces paw withdrawal responses during persistent nociception and hyperalgesia to heat in neuropathic pain models. ONO-2921 can be used for research on neuropathic pain and nociceptive pain.

Omtriptolide sodium (PG490-88Na) is a derivative of Triptolide. Omtriptolide sodium exhibits significant immunosuppressive, anti-fibrotic and anti-inflammatory properties. The mechanism of action of Omtriptolide sodium is diverse, including inhibiting T cell activation and proliferation, inducing T cell apoptosis (apoptosis), blocking fibroblast maturation/proliferation, inhibiting TGF-β mRNA expression, and suppressing pro-inflammatory cytokines (such as IL-2, IFN-γ, TNF-α) by blocking transcription factors such as NF-κB. Omtriptolide sodium can be used for research on obstructive airway diseases, pulmonary fibrosis and graft-versus-host disease.

Omocianine (Omocyanine) is a fluorescence imaging agent and has the potential to detect malignant breast lesions.

Omigapil (CGP3466B free base), an orally active GAPDH nitrosylation inhibitor, abrogates Aβ1-42-induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil has the potential for the research of Alzheimer's disease. Omigapil is a apoptosis inhibitor. Omigapil can be used for the research of congenital muscular dystrophy (CMD). Omigapil is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Omega-3 acid ethyl esters (P-OM3) is a omega-3 polyunsaturated fatty acid. Omega-3 acid ethyl esters can be used for the researches of severe hypertriglyceridemia and cardiovascular diseases.

Oltipraz metabolite M2, an active metabolite of Oltipraz, is an orally active HIF-1α inhibitor. Oltipraz metabolite M2 increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK in high-fat diet (HFD)-fed mice. Oltipraz metabolite M2 can be used for hepatic steatosis and steatohepatitis research.

Oleoylsulfamide is a cannabinoid receptor 1 inhibitor.

OK-1035 is a selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 of 100 μM.

OICR19451 is an orally active dual NUAK1/NUAK2 and MARK2/MARK3 kinase inhibitor, with IC50 values of 12 nM and 10 nM against NUAK1 and NUAK2, and 101 nM and 124 nM against MARK2 and MARK3, respectively. OICR19451 modulates the Hippo signaling pathway, increases the phosphorylation level of YAP, enhances the cytoplasmic localization of YAP/TAZ, and inhibits the expression of oncogenes. OICR19451 inhibits cancer cell growth, reduces metastasis, promotes tumor capsule formation, and improves mouse survival in an orthotopic breast cancer model. OICR19451 can be used for research related to triple-negative breast cancer.

OH14 is a cellular FLICE-like inhibitory protein (cFLIP) inhibitor and TNF-related apoptosis-inducing ligand (TRAIL) sensitizer. OH14 selectively binds to the DED1 pocket of cFLIP, disrupting its recruitment to the TRAIL-death inducing signalling complex without affecting procaspase-8 recruitment to FADD, allowing procaspase-8 activation. OH14 promotes TRAIL-mediated apoptosis and impairs cell viability in breast cancer systems when combined with TRAIL. OH14 can be used for the research of breast cancer.

Octoclothepine (Clorotepine), an analog of Clozapine, is a neuroleptic and antipsychotic agent. Octoclothepine exists in enantiomeric forms, where the (+)-form acts as an atypical antipsychotic, while the (-)-functions as a typical antipsychotic. (+)-Octoclothepine exhibits extremely high binding affinity for 5-HT₆ and 5-HT₇ receptors, with Ki values of 0.41 and 0.38 nM; the Ki values of (-)-Octoclothepine are 17.7 and 1.3 nM, respectively. Octoclothepine can be used in research related to schizophrenia.

Cholesterol-conjugated OC prodrug (Compound 1b) is an orally active cholesterol-bound prodrug of Oseltamivir carboxylate. Cholesterol-conjugated OC prodrug has a protective effect against influenza virus infection. The Oseltamivir carboxylate released by the Cholesterol-conjugated OC prodrug has a longer duration of circulation than the Oseltamivir carboxylate released from Oseltamivir. Cholesterol-conjugated OC prodrug can be used in influenza research.

O-Carboranylphenoxyacetanilide-1,7-dicarbadodecaboran(12) is a boron-containing organic compound.

OCA 983 is an orally active tetrahydrofuranyl 1β-methylcarbapenem antibiotic. OCA 983 exhibits potent inhibitory activity against class A and class C β-lactamases. OCA 983 possesses a broad antibacterial spectrum, and can be used in the research of infectious diseases.

Oberadilol (CID-3047798) is an ACE2 receptor binding agent. Oberadilol binds to the human ACE2 receptor and SARS-CoV proteins (Spike S glycoprotein, protease) with a Kd of 23.18 mM for the SARS-CoV-2 main protease.

O-1812 is a selective CB1 ligand. O-1812 is also a very weak AMT inhibitor. O-1812 can be used in the research of chronic pain, migraines, and inflammation.

NVP CXCR2 20 is a selective CXCR2 inhibitor with analgesic and antinociceptive activities. NVP CXCR2 20 selectively blocks CXCR2 signaling and attenuates mechanical and thermal hypersensitivity in rat chronic constriction injury (CCI) models. NVP CXCR2 20 inhibits CXCL3-induced hypersensitivity in naive mice and reduces elevated CXCL3 protein levels in the spinal cord and dorsal root ganglia (DRG) of CCI-exposed rats. NVP CXCR2 20 can be used for the research of neuropathic pain and chronic obstructive pulmonary disease (COPD).

Nurr1/RXR dual agonist 1 is a dual activator of Nurr1 (EC50 = 2.6 µM) and RXR with Ks of 0.6 and 1.1 µM, respectively. Nurr1/RXR dual agonist 1 exclusively activates the heterodimer response element DR5 by selectively destabilizing the Nurr1 homodimer and stabilizing the Nurr1:RXR heterodimer. Nurr1/RXR dual agonist 1 enhances expression of a specific subset of neuroprotective Nurr1 target genes while avoiding induction of genes associated with potential off-target effects in neuronal cells. Nurr1/RXR dual agonist 1 can be used for neurodegenerative diseases research.

NTPDase/NPP1-IN-1 is an ectonucleotidase (NTPDase) and nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) inhibitor, with IC50 values of 0.28, 0.92, 0.82 and 0.73 μM against h-NTPDase1, h-NTPDase2, h-NTPDase3 and h-NPP1, respectively. NTPDase/NPP1-IN-1 is a membrane-interacting agent that localizes to the plasma membrane and interacts with cancer cells. NTPDase/NPP1-IN-1 can be used in the research of breast cancer.

NSP-DMAE-HEG-Giu-NHS (Fig.18) is an activated labeling reagent containing acridine ester, and it is a key component of Cyclosporine A tracers.

NSD-IN-5 (Example 47) is a nuclear receptor-binding SET domain (NSD) inhibitor with IC5050 values ​​of 6 and < 1 nM for NSD1 and NSD2, respectively. NSD-IN-5 also exhibits inhibitory activity against Avg KMS11 cells with an IC5050 of 6 nM. NSD-IN-5 may be used in research on multiple myeloma.

NSD2-PWWP1-IN-5 (Compound 13) is an effective NSD2-PWWP1 inhibitor with a Kd value of 78 nM. NSD2-PWWP1-IN-5 competitively blocks the recognition of H3K36me2 and DNA by NSD2-PWWP1, thereby weakening its binding ability to nucleosomes. NSD2-PWWP1-IN-5 inhibits the proliferation of U2OS osteosarcoma cells and induces cell cycle arrest and apoptosis. NSD2-PWWP1-IN-5 can be used for the study of osteosarcoma.

NSC-624871 (JD-87), an analog of Miltefosine, is natural killer T-2 (NKT-2) activator. NSC-624871 activates type II NKT cells. NSC-624871 can be used for the study of SARS-CoV-2-mediated inflammatory conditions.

NSC127916 (compound Ib) is a 2,6-diaminopurine analogue of Methotrexate.

NSC126188 is a RhoB inducer. NSC126188 can induce apoptosis by inhibiting Akt/FoxO3 signaling. NSC126188 can be used for the research of cancer, such as prostate cancer.

NSC 660028 is a DNA topoisomerase II (DNA topoisomerase II) inhibitor with an ID50 of 50 μM. NSC 660028 inhibits DNA topoisomerase II and induces protein-linked DNA breaks. NSC 660028 can be used for cancer research.

NSC 121182 is a compound selected from NCI Diversity Set II by structure-based virtual screening. NSC 121182 can be used to study the Vitronectin-uPAR interaction. NSC 121182 can be used for cancer research.